Cargando…
Current challenges and unmet medical needs in myelodysplastic syndromes
Myelodysplastic syndromes (MDS) represent a heterogeneous group of myeloid neoplasms that are characterized by ineffective hematopoiesis, variable cytopenias, and a risk of progression to acute myeloid leukemia. Most patients with MDS are affected by anemia and anemia-related symptoms, which negativ...
Autores principales: | Platzbecker, Uwe, Kubasch, Anne Sophie, Homer-Bouthiette, Collin, Prebet, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324480/ https://www.ncbi.nlm.nih.gov/pubmed/34045662 http://dx.doi.org/10.1038/s41375-021-01265-7 |
Ejemplares similares
-
Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2018) -
Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2019) -
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape
por: Schwind, Sebastian, et al.
Publicado: (2021) -
Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
por: Cassanello, Giulio, et al.
Publicado: (2022) -
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)